Interpace Biosciences (IDXG) 10-Q/A 30 Sep 14 2013 Q3 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	9 Months Ended
	Sep. 30, 2013	Nov. 10, 2013
Entity Information [Line Items]	'	'
Entity Registrant Name	'PDI INC	'
Entity Central Index Key	'0001054102	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q/A	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	15,155,242

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheet (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
ASSETS	'	'
Cash and cash equivalents	$49,627	$52,783
Short-term investments	96	92
Accounts receivable, net	4,020	10,687
Unbilled costs and accrued profits on contracts in progress	6,645	1,955
Other current assets	6,136	6,066
Total current assets	66,524	71,583
Property and equipment, net	3,122	2,396
Goodwill	2,523	2,523
Other long-term assets	1,045	1,945
Total assets	73,214	78,447
LIABILITIES AND STOCKHOLDERS' EQUITY	'	'
Accounts payable	1,768	3,388
Unearned contract revenue	12,018	14,501
Accrued salary and bonus	7,631	6,674
Other accrued expenses	10,209	11,827
Total current liabilities	31,626	36,390
Long-term liabilities	5,581	6,427
Total liabilities	37,207	42,817
Commitments and contingencies (Note 7)	'	'
Stockholders’ equity:	'	'
Preferred stock, $.01 par value; 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.01 par value; 40,000,000 shares authorized; 16,281,305 and 16,063,514 shares issued, respectively; 15,149,357 and 14,965,875 shares outstanding, respectively	163	161
Additional paid-in capital	130,025	128,508
Accumulated deficit	-80,157	-79,258
Accumulated other comprehensive income	13	11
Treasury stock, at cost (1,131,948 and 1,097,639 shares, respectively)	-14,037	-13,792
Total stockholders' equity	36,007	35,630
Total liabilities and stockholders' equity	$73,214	$78,447

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheet (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred Stock, Par Value	$0.01	$0.01
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$0.01	$0.01
Common Stock, Shares Authorized	40,000,000	40,000,000
Common Stock, Shares, Issued	16,281,305	16,063,514
Common Stock, Shares, Outstanding	15,149,357	14,965,875
Treasury Stock, Shares	1,131,948	1,097,639

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenue, net	$34,260	$31,781	$114,428	$91,267
Cost of services	29,564	25,842	94,410	71,392
Gross profit	4,696	5,939	20,018	19,875
Compensation expense	4,231	4,075	13,300	12,726
Other selling, general and administrative expenses	2,517	2,620	7,364	8,442
Total operating expenses	6,748	6,695	20,664	21,168
Operating (loss) income	-2,052	-756	-646	-1,293
Other expense, net	3	0	-30	-15
(Loss) income from continuing operations before income tax	-2,049	-756	-676	-1,308
Provision (benefit) for income tax	64	74	192	219
(Loss) income from continuing operations	-2,113	-830	-868	-1,527
Income (loss) from discontinued operations, net of tax	-28	-189	-31	-204
Net (loss) income	-2,141	-1,019	-899	-1,731
Other Comprehensive Income (Loss)	'	'	'	'
Unrealized holding gain (loss) on available-for-sale securities, net	2	-1	2	-2
Comprehensive (loss) income	($2,139)	($1,020)	($897)	($1,733)
Basic (loss) income per share of common stock from:	'	'	'	'
Income (Loss) from Continuing Operations, Per Basic and Diluted Share	($0.14)	($0.06)	($0.06)	($0.10)
Discontinued operations	($0.01)	($0.01)	$0	($0.02)
Earnings Per Share, Basic and Diluted	($0.15)	($0.07)	($0.06)	($0.12)
Weighted average number of common shares and common share equivalents outstanding:	'	'	'	'
Basic	14,740	14,609	14,708	14,580
Diluted	14,740	14,609	14,708	14,580

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Provision for bad debt	$9	$0
Net income (loss)	-899	-1,731
Adjustments to reconcile net income (loss) to net cash provided by operating activities:	'	'
Depreciation and amortization	922	1,490
Contingent consideration and realignment accrual accretion	106	106
Stock-based compensation	1,519	1,520
Other changes in assets and liabilities:	'	'
Decrease in accounts receivable	6,658	1,368
(Increase) decrease in unbilled costs	-4,690	1,608
Decrease (increase) in other current assets	2,330	-477
Increase in other long-term assets	0	-6
Decrease in accounts payable	-1,620	-985
(Decrease) increase in unearned contract revenue	-2,483	368
Increase (decrease) in accrued salaries and bonus	957	-1,263
Decrease in other accrued expenses	-1,620	-3,813
Decrease in long-term liabilities	-952	-1,340
Net cash provided by (used in) operating activities	237	-3,155
Cash Flows From Investing Activities	'	'
Purchase of property and equipment	-1,648	-528
Investment in non-controlled entity	-1,500	0
Net cash used in investing activities	-3,148	-528
Cash Flows From Financing Activities	'	'
Cash paid for repurchase of restricted shares	-245	-125
Net cash used in financing activities	-245	-125
Net (decrease) increase in cash and cash equivalents	-3,156	-3,808
Cash and cash equivalents – beginning	52,783	64,337
Cash and cash equivalents – ending	$49,627	$60,529

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation [Text Block]	'
	BASIS OF PRESENTATION
	The accompanying unaudited interim condensed consolidated financial statements and related notes (the interim financial statements) should be read in conjunction with the consolidated financial statements of PDI, Inc. and its subsidiaries (the Company or PDI) and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 as filed with the Securities and Exchange Commission (SEC) on March 14, 2013.  The interim financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (GAAP) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements.  The interim financial statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements.  All significant intercompany balances and transactions have been eliminated in consolidation.  Operating results for the three and nine-month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies [Text Block]	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Accounting Estimates
	The preparation of the interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include incentives earned or penalties incurred on contracts, best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
	Basic and Diluted Net Loss per Share
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month periods ended September 30, 2013 and 2012 is as follows:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Basic weighted average number of common shares	14,740		14,609		14,708		14,580
	Dilutive effect of stock-based awards	—		—		—		—
	Diluted weighted average number of common shares	14,740		14,609		14,708		14,580
	The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
		Three Months Ended			Nine Months Ended
		September 30,			September 30,
		2013	2012		2013		2012
	Options	42	76		42		76
	Stock-settled stock appreciation rights (SARs)	796	574		796		574
	Restricted stock/units	600	632		600		632
	Performance contingent SARs	280	280		280		280
		1,718	1,562		1,718		1,562
	Goodwill and Other Intangible Assets
	The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the goodwill.
	The Company tests goodwill and indefinite lived intangible assets for impairment at least annually (as of December 31) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others: a significant decline in expected future cash flows; a sustained, significant decline in stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the pharmaceutical industry; unanticipated competition; and slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of goodwill and our consolidated financial results. At September 30, 2013, no indicators of impairment were identified.
	Cost of Services - Initial Direct Program Costs
	Initial direct program costs are the costs associated with initiating a product detailing program, such as recruiting and hiring and certain other direct incremental costs, excluding pass through costs that are billed to customers. Through March 31, 2012, the Company expensed these initial direct program costs as incurred, as these amounts were not material to the operating results of the Company.  As a result of the Company's recent contract signings and plans to enter into larger contracts in the future, requiring more material initial direct program costs, commencing April 1, 2012, the Company changed its policy for the recognition of such initial direct program costs. These costs are now being deferred and amortized to expense in proportion to the revenue recognized as driven by the terms of the contract. This change in accounting was not applied retrospectively because the effect on prior periods was immaterial.
	At September 30, 2013 and December 31, 2012, the Company deferred $2.3 million and $1.8 million of initial direct program costs, respectively.  For the three month and nine month periods ended September 30, 2013, the Company amortized $0.2 million and $0.7 million of initial direct program costs into expense, respectively.  For the three and nine month periods ended September 30, 2012, the Company amortized $0.1 million of initial direct program costs into expense.
	Accounting Standards Updates
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2013-02, Comprehensive Income (Topic 220), "Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income," effective for annual and interim reporting periods beginning after December 15, 2012. The new accounting rules require all U.S. public companies to report the effect of items reclassified out of accumulated other comprehensive income on the respective line items of net income, net of tax, either on the face of the financial statements where net income is presented or in a tabular format in the notes to the financial statements. Effective January 1, 2013, the Company adopted ASU No. 2013-02. The new accounting rules expand the disclosure of other comprehensive income and had no impact on the Company's results of operations and financial condition.

Investments_in_Marketable_Secu

Investments in Marketable Securities	9 Months Ended
	Sep. 30, 2013
Marketable Securities [Abstract]	'
Investments in Marketable Securities [Text Block]	'
	INVESTMENTS IN MARKETABLE SECURITIES
	Available-for-sale securities are carried at fair value with the unrealized holding gains or losses, net of tax, included as a component of accumulated other comprehensive income in stockholders’ equity. Realized gains and losses on available-for-sale securities are computed based upon specific identification and included in other income (expense), net in the consolidated statement of operations.  Declines in value judged to be other-than-temporary on available-for-sale securities are recorded in other income (expense), net in the consolidated statement of operations and the cost basis of the security is reduced. The fair values for marketable equity securities are based on quoted market prices.  Held-to-maturity investments are stated at amortized cost which approximates fair value.  Interest income is accrued as earned.  Realized gains and losses on held-to-maturity investments are computed based upon specific identification and included in other income (expense), net in the condensed consolidated statement of operations.  The Company does not have any investments classified as trading.
	Available-for-sale securities consist of assets in a rabbi trust associated with the Company’s deferred compensation plan.  As of September 30, 2013 and December 31, 2012, the carrying value of available-for-sale securities was approximately $96,000 and $92,000, respectively, and is included in short-term investments.  Available-for-sale securities at September 30, 2013 and December 31, 2012 consisted of $48,000 and $44,000, respectively, in mutual funds, and approximately $48,000 and $48,000, respectively, in money market accounts.
	The Company’s other marketable securities consist of investment grade debt instruments such as obligations of U.S. Treasury and U.S. Federal Government agencies.  These investments are categorized as held-to-maturity since the Company’s management has the ability and intent to hold these securities to maturity.  The Company’s held-to-maturity investments are carried at amortized cost which approximates fair value and are maintained in separate accounts to support the Company’s letters of credit.  The Company had standby letters of credit of approximately $2.0 million as of September 30, 2013 and $2.6 million at December 31, 2012, as collateral for its existing insurance policies and facility leases.
	At September 30, 2013 and December 31, 2012, held-to-maturity investments included the following:
				Maturing						Maturing
		September 30,		within		after 1 year		December 31,		within		after 1 year
		2013		1 year		through		2012		1 year		through
						3 years						3 years
	Cash/money accounts	$	44	$	44	$	—	$	76	$	76	$	—
	US Treasury securities	1,370		1,370		—		2,450		1,051		1,399
	Government agency securities	822		822		—		1,270		881		389
	Total	$	2,236	$	2,236	$	—	$	3,796	$	2,008	$	1,788
	At September 30, 2013 and December 31, 2012, held-to-maturity investments were recorded in the following accounts:
		September 30,		December 31,
		2013		2012
	Other current assets	$	1,349	$	2,008
	Other long-term assets	887		1,788
	Total	$	2,236	$	3,796

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets [Text Block]	'
	GOODWILL AND OTHER INTANGIBLE ASSETS
	Goodwill recorded as of September 30, 2013 is attributable to the 2010 acquisition of Group DCA.  As of September 30, 2013 and December 31, 2012, the carrying amount of goodwill for Group DCA was $2.5 million.
	No amortization expense was recorded in 2013 as the Company's finite lived intangible assets were written-off in the fourth quarter of 2012. Amortization expense was $0.2 million for the three-month period ended September 30, 2012 and $0.7 million for the nine-month period ended September 30, 2012.

Facilities_Realignment

Facilities Realignment	9 Months Ended
	Sep. 30, 2013
FACILITIES REALIGNMENT [Abstract]	'
Facilities Realignment [Text Block]	'
	FACILITIES REALIGNMENT
	The following table presents a rollforward of the Company’s restructuring reserve from December 31, 2012 to September 30, 2013, of which approximately $1.0 million is included in other accrued expenses and $1.2 million is included in long-term liabilities as of September 30, 2013. The Company recognizes accretion expense in Other income (expense), net in the Condensed Consolidated Statement of Operations and Comprehensive Loss.
		Sales			Marketing			Discontinued Operations			Total
		Services			Services
	Balance as of December 31, 2012	$	2,027		$	637		$	615		$	3,279
	Accretion	84			—			22			106
	Adjustments	—			—			—			—
	Payments	(841		)	(157		)	(211		)	(1,209		)
	Balance as of September 30, 2013	$	1,270		$	480		$	426		$	2,176

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements [Text Block]	'
	FAIR VALUE MEASUREMENTS
	The Company's financial assets and liabilities reflected at fair value in the consolidated financial statements include: cash and cash equivalents; short-term investments; accounts receivable; other current assets; accounts payable; and contingent consideration. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows:
	Level 1:	Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities.
	Level 2:	Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities.
	Level 3:	Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.
	In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.
	The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the table below.
		As of September 30, 2013				Fair Value Measurements
		Carrying		Fair		As of September 30, 2013
		Amount		Value		Level 1		Level 2		Level 3
	Assets:
	Cash and cash equivalents:
	Cash	$	12,303	$	12,303	$	12,303	$	—	$	—
	Money market funds	37,324		37,324		37,324		—		—
	Total	$	49,627	$	49,627	$	49,627	$	—	$	—
	Marketable securities:
	Money market funds	$	48	$	48	$	48	$	—	$	—
	Mutual funds	48		48		48		—		—
	U.S. Treasury securities	1,370		1,370		1,370		—		—
	Government agency securities	822		822		822		—		—
	Total	$	2,288	$	2,288	$	2,288	$	—	$	—
	The fair value of cash and cash equivalents and marketable securities is valued using market prices in active markets (level 1). As of September 30, 2013, the Company did not have any marketable securities in less active markets (level 2) or (level 3).
	The Company considers carrying amounts of accounts receivable, accounts payable and accrued expenses to approximate fair value due to the short-term nature of these financial instruments. There is no fair value ascribed to the letters of credit as management does not expect any material losses to result from these instruments because performance is not expected to be required.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies [Text Block]	'
	COMMITMENTS AND CONTINGENCIES
	Letters of Credit
	As of September 30, 2013, the Company had outstanding letters of credit of $2.0 million as required by its existing insurance policies and facility leases.  These letters of credit are supported by investments in held-to-maturity securities.  See Note 3, Investments in Marketable Securities, for additional detail regarding investments in marketable securities.
	Litigation
	Due to the nature of the businesses in which the Company is engaged, such as product detailing and in the past, the distribution of products, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or distributes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products, including pharmaceuticals. The Company seeks to reduce its potential liability under its service agreements through measures such as contractual indemnification provisions with customers (the scope of which may vary from customer to customer, and the performance of which is not secured) and insurance. The Company could, however, also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.
	The Company routinely assesses all of its litigation and threatened litigation as to the probability of ultimately incurring a liability, and records its best estimate of the ultimate loss in situations where the Company assesses the likelihood of loss as probable. The Company accrues for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In addition, in the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, as applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made.

Accrued_Expenses_and_LongTerm_

Accrued Expenses and Long-Term Liabilities	9 Months Ended
	Sep. 30, 2013
Other Liabilities Disclosure [Abstract]	'
Long-Term Liabilities [Text Block]	'
	Other accrued expenses consisted of the following as of September 30, 2013 and December 31, 2012:
		30-Sep-13		31-Dec-12
	Accrued pass-through costs	$	1,772	$	3,729
	Accrued reorganization expense	1,005		1,495
	Self insurance accruals	841		900
	Indemnification liability	875		875
	All others	5,716		4,828
		$	10,209	$	11,827
	Long-term liabilities consisted of the following as of September 30, 2013 and December 31, 2012:
		September 30, 2013		31-Dec-12
	Rent payable	$	1,187	$	1,533
	Uncertain tax positions	3,082		2,967
	Restructuring	1,171		1,785
	Other	141		142
		$	5,581	$	6,427

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation [Text Block]	'
	STOCK-BASED COMPENSATION
	On April 4, 2013, under the terms of the stockholder-approved PDI, Inc. 2004 Stock Award Incentive Plan (the 2004 Plan), the Compensation and Management Development Committee of the Board (the Compensation Committee) approved grants of restricted stock to certain executive officers and members of senior management of the Company. The full Board approved the portion of these grants made to the Company’s Chief Executive Officer.  As part of the Company's 2012 long-term incentive plan, these grants aggregated 143,695 shares of restricted stock issued with a grant date fair value of $5.44 per share and 396,760 SARs with grant date fair value of $1.97.
	The grant date fair values of SARs awards are determined using a Black-Scholes pricing model.  Assumptions utilized in the model are evaluated and revised, as necessary, to reflect market conditions and experience. The following table provides the weighted average assumptions used in determining the fair value of the non-performance based SARs awards granted during the nine months ended September 30, 2013 and 2012:
		Nine Months Ended
		30-Sep-13	30-Sep-12
	Risk-free interest rate	0.33%	0.31%
	Expected life (in years)	3.5	3.5
	Expected volatility	49.80%	57.62%
	Dividend yield	—%	—%
	The Company recognized $0.4 million and $0.5 million of stock-based compensation expense for the three-month periods ended September 30, 2013 and 2012, respectively, and $1.5 million for each of the nine-month periods ended September 30, 2013 and 2012.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes [Text Block]	'
	INCOME TAXES
	Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company's valuation allowance position and the existence of a deferred tax liability related to indefinite lived intangibles, it is the Company's position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method.  As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction.  The following table summarizes income tax expense on income from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2013 and 2012:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Provision for income tax	$	64		$	74		$	192		$	219
	Effective income tax rate	(3.1		)%	(9.8		)%	(28.4		)%	(16.7		)%
	Income tax expense for the nine-month periods ended September 30, 2013 and 2012 was primarily due to state and local taxes as the Company and its subsidiaries file separate income tax returns in numerous state and local jurisdictions.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Information [Text Block]	'
	SEGMENT INFORMATION
	The accounting policies of the segments are described in Note 1 of the Company’s audited consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2012.  Corporate charges are allocated to each of the reporting segments on the basis of total salary expense. Corporate charges include corporate headquarters costs and certain depreciation expenses. Certain corporate capital expenditures have not been allocated from the Sales Services segment to the other reporting segments since it is impracticable to do so.
		Sales			Marketing			Product Commercialization Services		Consolidated
		Services			Services
	Three months ended September 30, 2013:
	Revenue	$	30,748		$	781		$	2,731	$	34,260
	Operating (loss) income	$	(1,316	)	$	(1,177	)	$	441	$	(2,052	)
	Capital expenditures	$	290		$	402		$	—	$	692
	Depreciation expense	$	296		$	46		$	3	$	345
	Three months ended September 30, 2012:
	Revenue	$	25,021		$	2,196		$	4,564	$	31,781
	Operating (loss) income	$	(394	)	$	(1,326	)	$	964	$	(756	)
	Capital expenditures	$	73		$	7		$	—	$	80
	Depreciation expense	$	202		$	60		$	7	$	269
	Nine months ended September 30, 2013:
	Revenue	$	101,267		$	3,966		$	9,195	$	114,428
	Operating income (loss)	$	31		$	(2,378	)	$	1,701	$	(646	)
	Capital expenditures	$	545		$	1,103		$	—	$	1,648
	Depreciation expense	$	746		$	145		$	31	$	922
	Nine months ended September 30, 2012:
	Revenue	$	68,539		$	8,061		$	14,667	$	91,267
	Operating (loss) income	$	(1,524	)	$	(2,537	)	$	2,768	$	(1,293	)
	Capital expenditures	$	513		$	15		$	—	$	528
	Depreciation expense	$	575		$	195		$	43	$	813

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations [Text Block]	'
	DISCONTINUED OPERATIONS
	On December 29, 2011, we entered into an agreement to sell certain assets of our Pharmakon business unit to Informed in exchange for potential future royalty payments and a 1% ownership interest in Informed. The consolidated statement of operations reflects the presentation of Pharmakon as a discontinued operation in all periods presented.
	On July 19, 2010, the Board approved closing the TVG business unit. The Company completed the closure of the TVG operations during the quarter ended September 30, 2010, including the completion of all active customer contracts. The financial statements reflect the presentation of TVG as a discontinued operation in all periods presented.
	The table below presents the significant components of Pharmakon's and TVG’s results included in Loss from Discontinued Operations in the Condensed Consolidated Statements of Operations and Comprehensive Loss for the three- and nine-month periods ended September 30, 2013 and 2012.
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Revenue, net	$	—		$	—		$	—		$	—
	Loss from discontinued operations, before income tax	(27		)	(188		)	(27		)	(200		)
	Provision for income tax	1			1			4			4
	Loss from discontinued operations, net of tax	$	(28	)	$	(189	)	$	(31	)	$	(204	)
	The major classes of assets and liabilities included in the Condensed Consolidated Balance Sheets for TVG and Pharmakon as of September 30, 2013 and December 31, 2012 are as follows:
		September 30,			December 31,
		2013			2012
	Current assets	$	23		$	14
	Non-current assets	150			150
	Total assets	$	173		$	164
	Current liabilities	$	393		$	368
	Non-current liabilities	768			1,006
	Total liabilities	$	1,161		$	1,374

Subsequent_Event_Notes

Subsequent Event (Notes)	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	14	SUBSEQUENT EVENT
	In October 2013, the Company entered into a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by Transgenomic. Under the terms of the strategic collaboration agreement, the Company will be responsible for all U.S.-based marketing and promotion of CardioPredict™, while Transgenomic will be responsible for processing CardioPredict™ in its state-of-the-art CLIA lab and all customer support. Both parties will bear the cost of their respective expenses and will split profit on a formula basis. In addition, the Company will provide Transgenomic with funding support of up to 3.0 million, principally to mitigate working capital requirements.

Investment_in_NonControllable_

Investment in Non-Controllable Entity (Notes)	9 Months Ended
	Sep. 30, 2013
Investments, All Other Investments [Abstract]	'
Cost-method Investments, Description [Text Block]	'
	INVESTMENT IN NON-CONTROLLED ENTITY
	In August 2013, PDI entered into a collaboration agreement with a privately held, emerging molecular diagnostics company (the Diagnostics Company) to commercialize its fully-developed, molecular diagnostic tests. The Diagnostics Company does not have experience in, or a history of, successfully commercializing diagnostic products. Under the terms of the collaboration agreement, PDI paid an initial fee of $1.5 million and has received an option to purchase 100% of the outstanding common stock of the Diagnostics Company. The Company also has the option to contribute an additional $0.5 million for mutually agreed upon activities in furtherance of commercialization efforts. The option price is dependent on the achievement of certain milestones during the collaboration period (the period up to the exercise of the purchase option or termination of the collaboration agreement) and could be up to $6.0 million if all milestones are achieved at their maximum levels. PDI can terminate the collaboration agreement if all milestones are not achieved within one year and would receive a $1.0 million termination fee. If all milestones are achieved within one year and PDI has not exercised its option, the Diagnostics Company can require PDI to exercise the option to purchase its outstanding common stock or terminate the collaboration agreement and pay PDI a termination fee of approximately $2.0 million. If PDI purchases the outstanding common stock of the Diagnostic Company, in addition to the option price based on the achievement of milestones, beginning in 2015, PDI would pay a royalty of 7% on annual net revenue up to $50.0 million with escalating royalty percentages for higher annual net revenue capped at 11% for annual net revenue in excess of $100.0 million. For competitive reasons, the name of the Diagnostic Company and the specific focus area of the initial test to be commercialized are not being disclosed at this time.
	PDI has recorded the initial fee as an investment in a non-controlled entity within Other current assets in the Condensed Consolidated Balance Sheets in accordance with ASC 325-20 Investments Other - Cost Method Investments.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Accounting Estimates [Policy Text Block]	'
	Accounting Estimates
	The preparation of the interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the interim financial statements and the reported amounts of revenues and expenses during the reporting period.  Management's estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances.  Significant estimates include incentives earned or penalties incurred on contracts, best estimate of selling price in multiple element arrangements, valuation allowances related to deferred income taxes, self-insurance loss accruals, allowances for doubtful accounts and notes, income tax accruals, acquisition accounting, asset impairments and facilities realignment accruals.  The Company periodically reviews these matters and reflects changes in estimates as appropriate.  Actual results could materially differ from those estimates.
Goodwill and Other Intangible Assets [Policy Text Block]	'
	Goodwill and Other Intangible Assets
	The Company allocates the cost of acquired companies to the identifiable tangible and intangible assets acquired and liabilities assumed, with the remaining amount classified as goodwill. Since the entities the Company has acquired do not have significant tangible assets, a significant portion of the purchase price has been allocated to intangible assets and goodwill. The identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition, as well as the completion of impairment tests require significant management judgments and estimates. These estimates are made based on, among other factors, consultations with an accredited independent valuation consultant, reviews of projected future operating results and business plans, economic projections, anticipated highest and best use of future cash flows and the market participant cost of capital. The use of alternative estimates and assumptions could increase or decrease the estimated fair value of goodwill and other intangible assets, and potentially result in a different impact to the Company's results of operations. Further, changes in business strategy and/or market conditions may significantly impact these judgments thereby impacting the fair value of these assets, which could result in an impairment of the goodwill.
	The Company tests goodwill and indefinite lived intangible assets for impairment at least annually (as of December 31) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others: a significant decline in expected future cash flows; a sustained, significant decline in stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the pharmaceutical industry; unanticipated competition; and slower growth rates. Any adverse change in these factors could have a significant impact on the recoverability of goodwill and our consolidated financial results. At September 30, 2013, no indicators of impairment were identified.
Cost of Services - Initial Direct Program Costs [Policy Text Block]	'
	Cost of Services - Initial Direct Program Costs
	Initial direct program costs are the costs associated with initiating a product detailing program, such as recruiting and hiring and certain other direct incremental costs, excluding pass through costs that are billed to customers. Through March 31, 2012, the Company expensed these initial direct program costs as incurred, as these amounts were not material to the operating results of the Company.  As a result of the Company's recent contract signings and plans to enter into larger contracts in the future, requiring more material initial direct program costs, commencing April 1, 2012, the Company changed its policy for the recognition of such initial direct program costs. These costs are now being deferred and amortized to expense in proportion to the revenue recognized as driven by the terms of the contract. This change in accounting was not applied retrospectively because the effect on prior periods was immaterial.
	At September 30, 2013 and December 31, 2012, the Company deferred $2.3 million and $1.8 million of initial direct program costs, respectively.  For the three month and nine month periods ended September 30, 2013, the Company amortized $0.2 million and $0.7 million of initial direct program costs into expense, respectively.  For the three and nine month periods ended September 30, 2012, the Company amortized $0.1 million of initial direct program costs into expense.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Schedule of Weighted Average Number of Shares [Table Text Block]	'
	A reconciliation of the number of shares of common stock used in the calculation of basic and diluted loss per share for the three- and nine-month periods ended September 30, 2013 and 2012 is as follows:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Basic weighted average number of common shares	14,740		14,609		14,708		14,580
	Dilutive effect of stock-based awards	—		—		—		—
	Diluted weighted average number of common shares	14,740		14,609		14,708		14,580
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following outstanding stock-based awards were excluded from the computation of the effect of dilutive securities on loss per share for the following periods because they would have been anti-dilutive:
		Three Months Ended			Nine Months Ended
		September 30,			September 30,
		2013	2012		2013		2012
	Options	42	76		42		76
	Stock-settled stock appreciation rights (SARs)	796	574		796		574
	Restricted stock/units	600	632		600		632
	Performance contingent SARs	280	280		280		280
		1,718	1,562		1,718		1,562

Investments_in_Marketable_Secu1

Investments in Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2013
Marketable Securities [Abstract]	'
Investments Classified by Contractual Maturity Date [Table Text Block]	'
	At September 30, 2013 and December 31, 2012, held-to-maturity investments included the following:
				Maturing						Maturing
		September 30,		within		after 1 year		December 31,		within		after 1 year
		2013		1 year		through		2012		1 year		through
						3 years						3 years
	Cash/money accounts	$	44	$	44	$	—	$	76	$	76	$	—
	US Treasury securities	1,370		1,370		—		2,450		1,051		1,399
	Government agency securities	822		822		—		1,270		881		389
	Total	$	2,236	$	2,236	$	—	$	3,796	$	2,008	$	1,788
Held-to-maturity Securities [Table Text Block]	'
	At September 30, 2013 and December 31, 2012, held-to-maturity investments were recorded in the following accounts:
		September 30,		December 31,
		2013		2012
	Other current assets	$	1,349	$	2,008
	Other long-term assets	887		1,788
	Total	$	2,236	$	3,796

Facilities_Realignment_Tables

Facilities Realignment (Tables)	9 Months Ended
	Sep. 30, 2013
FACILITIES REALIGNMENT [Abstract]	'
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	'
		Sales			Marketing			Discontinued Operations			Total
		Services			Services
	Balance as of December 31, 2012	$	2,027		$	637		$	615		$	3,279
	Accretion	84			—			22			106
	Adjustments	—			—			—			—
	Payments	(841		)	(157		)	(211		)	(1,209		)
	Balance as of September 30, 2013	$	1,270		$	480		$	426		$	2,176

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the table below.
		As of September 30, 2013				Fair Value Measurements
		Carrying		Fair		As of September 30, 2013
		Amount		Value		Level 1		Level 2		Level 3
	Assets:
	Cash and cash equivalents:
	Cash	$	12,303	$	12,303	$	12,303	$	—	$	—
	Money market funds	37,324		37,324		37,324		—		—
	Total	$	49,627	$	49,627	$	49,627	$	—	$	—
	Marketable securities:
	Money market funds	$	48	$	48	$	48	$	—	$	—
	Mutual funds	48		48		48		—		—
	U.S. Treasury securities	1,370		1,370		1,370		—		—
	Government agency securities	822		822		822		—		—
	Total	$	2,288	$	2,288	$	2,288	$	—	$	—

Accrued_Expenses_and_LongTerm_1

Accrued Expenses and Long-Term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Other Liabilities Disclosure [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Other accrued expenses consisted of the following as of September 30, 2013 and December 31, 2012:
		30-Sep-13		31-Dec-12
	Accrued pass-through costs	$	1,772	$	3,729
	Accrued reorganization expense	1,005		1,495
	Self insurance accruals	841		900
	Indemnification liability	875		875
	All others	5,716		4,828
		$	10,209	$	11,827
Long-term Liabilities [Table Text Block]	'
	Long-term liabilities consisted of the following as of September 30, 2013 and December 31, 2012:
		September 30, 2013		31-Dec-12
	Rent payable	$	1,187	$	1,533
	Uncertain tax positions	3,082		2,967
	Restructuring	1,171		1,785
	Other	141		142
		$	5,581	$	6,427

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Nine Months Ended
		30-Sep-13	30-Sep-12
	Risk-free interest rate	0.33%	0.31%
	Expected life (in years)	3.5	3.5
	Expected volatility	49.80%	57.62%
	Dividend yield	—%	—%

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The following table summarizes income tax expense on income from continuing operations and the effective tax rate for the three- and nine-month periods ended September 30, 2013 and 2012:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Provision for income tax	$	64		$	74		$	192		$	219
	Effective income tax rate	(3.1		)%	(9.8		)%	(28.4		)%	(16.7		)%

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
		Sales			Marketing			Product Commercialization Services		Consolidated
		Services			Services
	Three months ended September 30, 2013:
	Revenue	$	30,748		$	781		$	2,731	$	34,260
	Operating (loss) income	$	(1,316	)	$	(1,177	)	$	441	$	(2,052	)
	Capital expenditures	$	290		$	402		$	—	$	692
	Depreciation expense	$	296		$	46		$	3	$	345
	Three months ended September 30, 2012:
	Revenue	$	25,021		$	2,196		$	4,564	$	31,781
	Operating (loss) income	$	(394	)	$	(1,326	)	$	964	$	(756	)
	Capital expenditures	$	73		$	7		$	—	$	80
	Depreciation expense	$	202		$	60		$	7	$	269
	Nine months ended September 30, 2013:
	Revenue	$	101,267		$	3,966		$	9,195	$	114,428
	Operating income (loss)	$	31		$	(2,378	)	$	1,701	$	(646	)
	Capital expenditures	$	545		$	1,103		$	—	$	1,648
	Depreciation expense	$	746		$	145		$	31	$	922
	Nine months ended September 30, 2012:
	Revenue	$	68,539		$	8,061		$	14,667	$	91,267
	Operating (loss) income	$	(1,524	)	$	(2,537	)	$	2,768	$	(1,293	)
	Capital expenditures	$	513		$	15		$	—	$	528
	Depreciation expense	$	575		$	195		$	43	$	813

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
		September 30,			December 31,
		2013			2012
	Current assets	$	23		$	14
	Non-current assets	150			150
	Total assets	$	173		$	164
	Current liabilities	$	393		$	368
	Non-current liabilities	768			1,006
	Total liabilities	$	1,161		$	1,374
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Revenue, net	$	—		$	—		$	—		$	—
	Loss from discontinued operations, before income tax	(27		)	(188		)	(27		)	(200		)
	Provision for income tax	1			1			4			4
	Loss from discontinued operations, net of tax	$	(28	)	$	(189	)	$	(31	)	$	(204	)

Basis_of_Presentation_Details

Basis of Presentation (Details)	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	1.00%

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Shares outstanding) (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Accounting Policies [Abstract]	'	'	'	'
Basic weighted average number of common shares	14,740	14,609	14,708	14,580
Dilutive effect of stock-based awards	0	0	0	0
Diluted weighted average number of common shares	14,740	14,609	14,708	14,580

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Anti-dilutive shares) (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,718	1,562	1,718	1,562
Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	42	76	42	76
Stock-settled stock appreciation rights (SARs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	796	574	796	574
Restricted stock/units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	600	632	600	632
Performance contingent SARs [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	280	280	280	280

Summary_of_Significant_Account5

Summary of Significant Accounting Policies Contract costs (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2012	Sep. 30, 2013
Contract Start-up Costs [Abstract]	'	'	'
Amortization	$200	$100	$700

Investments_in_Marketable_Secu2

Investments in Marketable Securities (Held to Maturity Securities, by Maturity) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Schedule of Held-to-maturity Securities [Line Items]	'	'
Short-term Investments	$1,349,000	'
Available-for-sale Securities	96,000	92,000
Letters of Credit Outstanding, Amount	2,000,000	2,600,000
Held-to-maturity Securities, Current	2,236,000	2,008,000
Held-to-maturity Securities, Noncurrent	0	1,788,000
Held-to-maturity Securities, Total	2,236,000	3,796,000
Long-term Investments	887,000	'
Mutual Funds [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Available-for-sale Securities	48,000	44,000
Cash/Money Market Accounts [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Available-for-sale Securities	48,000	48,000
Held-to-maturity Securities, Current	44,000	76,000
Held-to-maturity Securities, Noncurrent	0	0
Held-to-maturity Securities, Total	44,000	76,000
US Treasury Securities [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Held-to-maturity Securities, Current	1,370,000	1,051,000
Held-to-maturity Securities, Noncurrent	0	1,399,000
Held-to-maturity Securities, Total	1,370,000	2,450,000
US Government Agencies Securities [Member]	'	'
Schedule of Held-to-maturity Securities [Line Items]	'	'
Held-to-maturity Securities, Current	822,000	881,000
Held-to-maturity Securities, Noncurrent	0	389,000
Held-to-maturity Securities, Total	$822,000	$1,270,000

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Details) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'	'	'
Goodwill	'	'	$2,523,000	$2,523,000
Amortization of Intangible Assets	$200,000	$700,000	'	'

Facilities_Realignment_Details

Facilities Realignment (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Restructuring Cost and Reserve [Line Items]	'	'	'
Restructuring Reserve, Current	$1,005	'	$1,495
Restructuring Reserve, Noncurrent	1,171	'	1,785
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2011	3,279	'	'
Accretion	106	106	'
Adjustments	0	'	'
Payments	-1,209	'	'
Restructuring Reserve, Balance as of June 30, 2012	2,176	'	'
Sales Services [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2011	2,027	'	'
Accretion	84	'	'
Adjustments	0	'	'
Payments	-841	'	'
Restructuring Reserve, Balance as of June 30, 2012	1,270	'	'
Marketing Services [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2011	637	'	'
Accretion	0	'	'
Adjustments	0	'	'
Payments	-157	'	'
Restructuring Reserve, Balance as of June 30, 2012	480	'	'
Segment, Discontinued Operations [Member]	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Restructuring Reserve, Balance as of December 31, 2011	615	'	'
Accretion	22	'	'
Adjustments	0	'	'
Payments	-211	'	'
Restructuring Reserve, Balance as of June 30, 2012	$426	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Available-for-sale Securities	$96	$92
Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	49,627	'
Marketable Securities, Fair Value Disclosure	2,288	'
Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	49,627	'
Marketable Securities, Fair Value Disclosure	2,288	'
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	49,627	'
Marketable Securities, Fair Value Disclosure	2,288	'
Money Market Funds [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48	'
Money Market Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48	'
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48	'
Mutual Funds [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48	'
Mutual Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48	'
Mutual Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	48	'
US Treasury Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	1,370	'
US Treasury Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	1,370	'
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	1,370	'
US Government Agencies Securities [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	822	'
US Government Agencies Securities [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	822	'
US Government Agencies Securities [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Marketable Securities, Fair Value Disclosure	822	'
Cash [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	12,303	'
Cash [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	12,303	'
Cash [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	12,303	'
Money Market Funds [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	37,324	'
Money Market Funds [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	37,324	'
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$37,324	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'	'
Letters of Credit Outstanding, Amount	$2	$2.60

Accrued_Expenses_and_LongTerm_2

Accrued Expenses and Long-Term Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Other Liabilities Disclosure [Abstract]	'	'
Other Liabilities	$1,772	$3,729
Accrued reorganization expense	1,005	1,495
Rent Payable	1,187	1,533
Uncertain Tax Positions	3,082	2,967
Restructuring	1,171	1,785
Other	141	142
Total Long-Term Liabilities	5,581	6,427
Self insurance accruals	841	900
Indemnification liability	875	875
All others	5,716	4,828
Other accrued expenses	$10,209	$11,827

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 04, 2013	Apr. 04, 2013
					Management [Member]	Management [Member]
					Restricted Stock [Member]	Stock Appreciation Rights (SARs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	'	'	$5.44	$1.97
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	'	143,695	396,760
Risk-free Interest Rate	'	'	0.33%	0.31%	'	'
Expected life (in years)	'	'	'3 years 6 months	'3 years 6 months	'	'
Expected volatility	'	'	49.80%	57.62%	'	'
Dividend Yield	'	'	0.00%	0.00%	'	'
Stock-based Compensation Expense	$400	$500	$1,519	$1,520	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Tax Disclosure [Abstract]	'	'	'	'
Provision (benefit) for income tax	$64	$74	$192	$219
Effective Income Tax Rate	-3.10%	-9.80%	-28.40%	-16.70%

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	$34,260	$31,781	$114,428	$91,267
Operating (loss) income	-2,052	-756	-646	-1,293
Capital expenditures	692	80	1,648	528
Depreciation expense	345	269	922	813
Sales Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	30,748	25,021	101,267	68,539
Operating (loss) income	-1,316	-394	31	-1,524
Capital expenditures	290	73	545	513
Depreciation expense	296	202	746	575
Marketing Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	781	2,196	3,966	8,061
Operating (loss) income	-1,177	-1,326	-2,378	-2,537
Capital expenditures	402	7	1,103	15
Depreciation expense	46	60	145	195
Product Commercialization Services [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenues	2,731	4,564	9,195	14,667
Operating (loss) income	441	964	1,701	2,768
Capital expenditures	0	0	0	0
Depreciation expense	$3	$7	$31	$43

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Discontinued Operations and Disposal Groups [Abstract]	'	'	'	'	'
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	'	'	'	'	1.00%
Revenue, net	$0	$0	$0	$0	'
(Loss) income from discontinued operations, before income tax	-27,000	-188,000	-27,000	-200,000	'
Provision (benefit) for income tax	1,000	1,000	4,000	4,000	'
Income (loss) from discontinued operations, net of tax	-28,000	-189,000	-31,000	-204,000	'
Current assets	23,000	'	23,000	'	14,000
Non-current assets	150,000	'	150,000	'	150,000
Total assets	173,000	'	173,000	'	164,000
Current liabilities	393,000	'	393,000	'	368,000
Non-current liabilities	768,000	'	768,000	'	1,006,000
Total liabilities	$1,161,000	'	$1,161,000	'	$1,374,000

Subsequent_Event_Details

Subsequent Event (Details) (Subsequent Event [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Subsequent Event [Member]	'
Subsequent Event [Line Items]	'
Collaborative arrangement, expected working capital requirements payments	$3

Investment_in_NonControllable_1

Investment in Non-Controllable Entity (Details) (Diagnostics Company [Member], USD $)	1 Months Ended	9 Months Ended
	Aug. 31, 2013	Sep. 30, 2013
Diagnostics Company [Member]	'	'
Schedule of Cost-method Investments [Line Items]	'	'
Cost Method Investments	'	$1,500,000
Option To Purchase	'	100.00%
Cost method investments, additional investment	500,000	'
Collaborative arrangement, potential maximum stock option price	6,000,000	'
Business Combination, Indemnification Assets, Range of Outcomes, Value, Low	1,000,000	'
Business Combination, Indemnification Assets, Range of Outcomes, Value, High	2,000,000	'
Royalty Percentage - Minimum range	7.00%	'
Revenue Range, Minimum	50,000,000	'
Royalty Percentage - Maximum Range	11.00%	'
Revenue Range - Maximum	'	$100,000,000